We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+25.89%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$1.2B
AUM Growth
+$101M
Cap. Flow
-$127M
Cap. Flow %
-10.58%
Top 10 Hldgs %
84.52%
Holding
38
New
5
Increased
5
Reduced
6
Closed
6

Top Buys

Rank Stock Value
1
SPRY icon
ARS Pharmaceuticals
SPRY
+$23M
2
TEM
Tempus AI
TEM
+$20.6M
3
INCY icon
Incyte
INCY
+$7.9M
4
UNH icon
UnitedHealth
UNH
+$7.56M
5
GPCR icon
Structure Therapeutics
GPCR
+$6.57M

Top Sells

Rank Stock Value
1
WGS icon
GeneDx Holdings
WGS
+$54.5M
2
VERV
Verve Therapeutics
VERV
+$46M
3
BLFS icon
BioLife Solutions
BLFS
+$23.7M
4
CDXS icon
Codexis
CDXS
+$17.6M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$16.9M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WGS icon
1
GeneDx Holdings
WGS
$1.98B
$324M 27.01%
3,007,164
-500,000
-14% -$54.5M
BLFS icon
2
BioLife Solutions
BLFS
$1.56B
$171M 14.27%
6,707,165
-1,000,000
-13% -$23.7M
RVMD icon
3
Revolution Medicines
RVMD
$38.8B
$124M 10.31%
2,647,333
-240,600
-8% -$9.42M
LAB icon
4
Standard BioTools
LAB
$343M
$101M 8.41%
77,558,856
+1,483,220
+2% +$1.94M
RNAM
5
DELISTED
Avidity Biosciences
RNAM
$77.6M 6.47%
1,780,000
+5,000
+0.3% +$202K
RLAY icon
6
Relay Therapeutics
RLAY
$4.04B
$59.2M 4.94%
11,341,381
-57,193
-0.5% -$218K
ILMN icon
7
Illumina
ILMN
$30.2B
$49.9M 4.16%
525,000
-120,000
-19% -$11.9M
GPCR icon
8
Structure Therapeutics
GPCR
$3.39B
$43.5M 3.63%
1,555,000
+330,000
+27% +$6.57M
BEAM icon
9
Beam Therapeutics
BEAM
$2.66B
$38.8M 3.24%
1,600,000
+150,000
+10% +$2.98M
ALNY icon
10
Alnylam Pharmaceuticals
ALNY
$29.1B
$25.1M 2.09%
55,000
-26,500
-33% -$10.8M
TEM
11
Tempus AI
TEM
$8.44B
$23.7M 1.98%
+294,127
New +$20.6M
NGNE icon
12
Neurogene
NGNE
$657M
$22.4M 1.87%
1,295,361
– –
MAZE
13
Maze Therapeutics
MAZE
$1.49B
$19.7M 1.64%
758,857
– –
PRME icon
14
Prime Medicine
PRME
$515M
$17.5M 1.46%
3,167,175
+1,600,000
+102% +$6.5M
SPRY icon
15
ARS Pharmaceuticals
SPRY
$530M
$16.1M 1.34%
+1,600,000
New +$23M
HIMS icon
16
Hims & Hers Health
HIMS
$7.12B
$13M 1.09%
230,000
– –
DNLI icon
17
Denali Therapeutics
DNLI
$3.67B
$12.9M 1.08%
890,000
– –
SEPN
18
Septerna Inc
SEPN
$1.57B
$10.4M 0.87%
553,268
– –
VCYT icon
19
Veracyte
VCYT
$3.6B
$9.49M 0.79%
276,308
– –
UNH icon
20
UnitedHealth
UNH
$378B
$8.63M 0.72%
+25,000
New +$7.56M
INCY icon
21
Incyte
INCY
$24.1B
$8.48M 0.71%
+100,000
New +$7.9M
GH icon
22
Guardant Health
GH
$21.6B
$6.25M 0.52%
100,000
– –
EXAS
23
DELISTED
Exact Sciences
EXAS
$4.92M 0.41%
90,000
– –
BBOT
24
BridgeBio Oncology
BBOT
$656M
$3.27M 0.27%
+282,312
New +$2.94M
ABSI icon
25
Absci
ABSI
$1.34B
$2.96M 0.25%
973,260
– –
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MIM
Marco Investment Management Atlanta, Georgia $1.33B AUM 32.43% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
MCM
Mill Capital Management Concord, North Carolina $1.31B AUM 17.4% 1-Year Est. Return
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return

Casdin Capital's Q3 2025 Portfolio in Review

As of Q3 2025, Casdin Capital held 38 positions worth $1.2B, up 9.2% from $1.1B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Casdin Capital withdrew a net $127M in Q3 2025, closing 6 positions and reducing 6 holdings. Its most notable exit was Verve Therapeutics, an estimated $46M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Casdin Capital opened a new position in ARS Pharmaceuticals worth $16.1M.

  • Casdin Capital's largest Q3 2025 buy was ARS Pharmaceuticals: 1,600,000 shares worth $16.1M.
  • Casdin Capital added most to Structure Therapeutics in Q3 2025, an estimated $6.57M increase.
  • Casdin Capital's biggest Q3 2025 reduction was GeneDx Holdings, cutting an estimated $54.5M.
  • Casdin Capital fully exited Verve Therapeutics in Q3 2025, selling an estimated $46M.
  • Casdin Capital's ten largest holdings make up 85% of its $1.2B portfolio in Q3 2025.
  • Casdin Capital opened 5 new positions and closed 6 in Q3 2025.
  • Casdin Capital's portfolio value rose 9.2% quarter-over-quarter to $1.2B.

Based on Casdin Capital's 13F filing for Q3 2025, filed 14 Nov 2025.